Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Gastric Cancer: Update Bulletin #2 [December 2018]

Product Code:
Publication Date:
December 2018

This edition presents key opinion leader (KOL) views on recent developments in the treatment of gastric cancer (GC). Topics covered include KOL views on; Leap Therapeutics presentation of data from the P102 study for DKN-01, an anti-dickkopf homolog 1 (anti-DKK1) monoclonal antibody (mAb), in combination with paclitaxel, or Keytruda (pembrolizumab; Merck & Co.), in patients with advanced gastroesophageal cancer (GEC); Five Prime Therapeutics’ announcing that Phase I of the FIGHT clinical study evaluating mAb bemarituzumab in advanced gastric cancer and gastroesophageal junction cancer has been completed and the therapy is progressing to a Phase III registration study; and CARsgen’s chimeric antigen receptor T-cell (CAR-T) therapy CAR-Claudin18.2, following presentation of positive preliminary data at the 2018 CAR-TCR Summit in Boston in September 2018.

Business Questions:

• How do KOLs view the potential of Leap Pharmaceuticals’ anti-DKK1 mAb DKN-01targets the Wnt pathway, given the uncertainty with regard to the role of this pathway in the pathogenesis of cancer?
• How do KOLs view the preliminary data for DKN-01/Keytruda (pembrolizumab, Eli Lilly) combination and do they agree thatit indicates a synergistic effect in patients that would otherwise be unresponsive to anti-PD1 immunotherapy?
• Could the combination of DKN-O1 with chemotherapy agent paclitaxel represent a more promising treatment option for GC patients?
• Do KOLs believe that Five Prime Therapeutics’ FGFR2b targeting mAb bemiratuzumab offers a promising approach for the treatment of GC, given prior failure of drugs targeting the fibroblast growth factor pathway?
• What challenges does Five Prime Therapeutics face as it moves bemarituzumab into Phase III development? How confident are KOLs that bemarituzumab can meet the primary endpoint of overall survival in the ongoing Phase III study?
• Bemarituzumab has been evaluated in advanced gastric cancer patients, but Five Prime Therapeutics is combining the therapy with the mFOLFOX6 chemotherapy regimen as a first-line option in the treatment of GC. Do KOLs consider this to be a commercially viable strategy?
• How optimistic are KOLs with regard to CARsgen’s chimeric antigen receptor T-cell based (CAR-T) therapy, CAR-Claudin18.2, following presentation of preliminary data from a small cohort of relapsed/refractory GC patients?
• What challenges do KOLs perceive that CAR-Claudin18.2 might encounter that would limit CAR-Claudin18.2’s potential in the GC field?
• If successful, where might CAR-Claudin18.2 sit within the current treatment paradigm?


All Contents Copyright © 2020 Doctor's Guide Publishing Limited All Rights Reserved